Travere Therapeutics names new R&D head ahead of 2027 retirement

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. META
10. TLT

Go back to Travere Therapeutics names new R&D head ahead of 2027 retirement

Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027

June 16, 2026 4:30 PM EDT

William Rote, Ph.D., chief research officer plans to retire in early 2027

Jula Inrig, M.D., to be named executive vice president, head of research and development and CMO, expanding her responsibilities to include the Companys research organization

SAN DIEGO--(BUSINESS WIRE)-- Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that William Rote, Ph.D., the Companys chief research officer, plans to retire from the Company in February 2027 following 10 years of service. Jula Inrig, M.D., currently chief medical officer and a member of the... More